480 related articles for article (PubMed ID: 33479401)
1. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.
Jena AB; Kanungo N; Nayak V; Chainy GBN; Dandapat J
Sci Rep; 2021 Jan; 11(1):2043. PubMed ID: 33479401
[TBL] [Abstract][Full Text] [Related]
2. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
Rui L; Haonan L; Wanyi C
Biophys Chem; 2020 Dec; 267():106472. PubMed ID: 32916377
[TBL] [Abstract][Full Text] [Related]
3. Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity.
Chakraborty S
Biochem Biophys Res Commun; 2021 Jan; 538():97-103. PubMed ID: 33602511
[TBL] [Abstract][Full Text] [Related]
4. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
5. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
6. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.
Maiti S; Banerjee A
Drug Dev Res; 2021 Feb; 82(1):86-96. PubMed ID: 32770567
[TBL] [Abstract][Full Text] [Related]
9. Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity.
Chakraborty S
Biochem Biophys Res Commun; 2021 Jan; 534():374-380. PubMed ID: 33272568
[TBL] [Abstract][Full Text] [Related]
10. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
[TBL] [Abstract][Full Text] [Related]
12. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.
Kalathiya U; Padariya M; Fahraeus R; Chakraborti S; Hupp TR
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671255
[TBL] [Abstract][Full Text] [Related]
13. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.
Tanaka S; Nelson G; Olson CA; Buzko O; Higashide W; Shin A; Gonzalez M; Taft J; Patel R; Buta S; Richardson A; Bogunovic D; Spilman P; Niazi K; Rabizadeh S; Soon-Shiong P
Sci Rep; 2021 Jun; 11(1):12740. PubMed ID: 34140558
[TBL] [Abstract][Full Text] [Related]
14. S494 O-glycosylation site on the SARS-CoV-2 RBD affects the virus affinity to ACE2 and its infectivity; a molecular dynamics study.
Rahnama S; Azimzadeh Irani M; Amininasab M; Ejtehadi MR
Sci Rep; 2021 Jul; 11(1):15162. PubMed ID: 34312429
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
[TBL] [Abstract][Full Text] [Related]
16. Insilico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability.
Verma J; Subbarao N
Virology; 2021 Sep; 561():107-116. PubMed ID: 34217923
[TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
18. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
19. Tetracycline as an inhibitor to the SARS-CoV-2.
Zhao TY; Patankar NA
J Cell Biochem; 2021 Jul; 122(7):752-759. PubMed ID: 33619758
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the transmission feasibility of SARS-CoV-2 Omicron (B.1.1.529) variant to 143 mammalian hosts: insights from S protein RBD and host ACE2 interaction studies.
Samanta A; Alam SSM; Ali S; Hoque M
Funct Integr Genomics; 2023 Jan; 23(1):36. PubMed ID: 36631570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
